Targeting the C-type Lectins-Mediated Host-Pathogen Interactions with Dextran

Dextran, the α-1,6-linked glucose polymer widely used in biology and medicine, promises new applications. Linear dextran applied as a blood plasma substitute demonstrates a high rate of biocompatibility. Dextran is present in foods, drugs, and vaccines and in most cases is applied as a biologically...

Full description

Bibliographic Details
Main Authors: Sergey Pustylnikov, Divya Sagar, Pooja Jain, Zafar K Khan
Format: Article
Language:English
Published: Canadian Society for Pharmaceutical Sciences 2014-08-01
Series:Journal of Pharmacy & Pharmaceutical Sciences
Online Access:https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/22139
id doaj-baa7946e50c34ff487161917696423af
record_format Article
spelling doaj-baa7946e50c34ff487161917696423af2020-11-25T03:41:23ZengCanadian Society for Pharmaceutical SciencesJournal of Pharmacy & Pharmaceutical Sciences1482-18262014-08-0117310.18433/J3N590Targeting the C-type Lectins-Mediated Host-Pathogen Interactions with DextranSergey Pustylnikov0Divya Sagar1Pooja Jain2Zafar K Khan3Group of Molecular Biology Research, Novosibirsk Tuberculosis Research Institute, Novosibirsk, Russia. Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. Dextran, the α-1,6-linked glucose polymer widely used in biology and medicine, promises new applications. Linear dextran applied as a blood plasma substitute demonstrates a high rate of biocompatibility. Dextran is present in foods, drugs, and vaccines and in most cases is applied as a biologically inert substance. In this review we analyze dextran's cellular uptake principles, receptor specificity and, therefore, its ability to interfere with pathogen–lectin interactions: a promising basis for new antimicrobial strategies. Dextran-binding receptors in humans include the DC-SIGN (dendritic cell–specific intercellular adhesion molecule 3-grabbing nonintegrin) family receptors: DC-SIGN (CD209) and L-SIGN (the liver and lymphatic endothelium homologue of DC-SIGN), the mannose receptor (CD206), and langerin. These receptors take part in the uptake of pathogens by dendritic cells and macrophages and may also participate in the modulation of immune responses, mostly shown to be beneficial for pathogens per se rather than host(s). It is logical to predict that owing to receptor-specific interactions, dextran or its derivatives can interfere with these immune responses and improve infection outcome. Recent data support this hypothesis. We consider dextran a promising molecule for the development of lectin–glycan interaction-blocking molecules (such as DC-SIGN inhibitors) that could be applied in the treatment of diseases including tuberculosis, influenza, hepatitis B and C, human immunodeficiency virus infection and AIDS, etc. Dextran derivatives indeed change the pathology of infections dependent on DC-SIGN and mannose receptors. Complete knowledge of specific dextran–lectin interactions may also be important for development of future dextran applications in biological research and medicine.   This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/22139
collection DOAJ
language English
format Article
sources DOAJ
author Sergey Pustylnikov
Divya Sagar
Pooja Jain
Zafar K Khan
spellingShingle Sergey Pustylnikov
Divya Sagar
Pooja Jain
Zafar K Khan
Targeting the C-type Lectins-Mediated Host-Pathogen Interactions with Dextran
Journal of Pharmacy & Pharmaceutical Sciences
author_facet Sergey Pustylnikov
Divya Sagar
Pooja Jain
Zafar K Khan
author_sort Sergey Pustylnikov
title Targeting the C-type Lectins-Mediated Host-Pathogen Interactions with Dextran
title_short Targeting the C-type Lectins-Mediated Host-Pathogen Interactions with Dextran
title_full Targeting the C-type Lectins-Mediated Host-Pathogen Interactions with Dextran
title_fullStr Targeting the C-type Lectins-Mediated Host-Pathogen Interactions with Dextran
title_full_unstemmed Targeting the C-type Lectins-Mediated Host-Pathogen Interactions with Dextran
title_sort targeting the c-type lectins-mediated host-pathogen interactions with dextran
publisher Canadian Society for Pharmaceutical Sciences
series Journal of Pharmacy & Pharmaceutical Sciences
issn 1482-1826
publishDate 2014-08-01
description Dextran, the α-1,6-linked glucose polymer widely used in biology and medicine, promises new applications. Linear dextran applied as a blood plasma substitute demonstrates a high rate of biocompatibility. Dextran is present in foods, drugs, and vaccines and in most cases is applied as a biologically inert substance. In this review we analyze dextran's cellular uptake principles, receptor specificity and, therefore, its ability to interfere with pathogen–lectin interactions: a promising basis for new antimicrobial strategies. Dextran-binding receptors in humans include the DC-SIGN (dendritic cell–specific intercellular adhesion molecule 3-grabbing nonintegrin) family receptors: DC-SIGN (CD209) and L-SIGN (the liver and lymphatic endothelium homologue of DC-SIGN), the mannose receptor (CD206), and langerin. These receptors take part in the uptake of pathogens by dendritic cells and macrophages and may also participate in the modulation of immune responses, mostly shown to be beneficial for pathogens per se rather than host(s). It is logical to predict that owing to receptor-specific interactions, dextran or its derivatives can interfere with these immune responses and improve infection outcome. Recent data support this hypothesis. We consider dextran a promising molecule for the development of lectin–glycan interaction-blocking molecules (such as DC-SIGN inhibitors) that could be applied in the treatment of diseases including tuberculosis, influenza, hepatitis B and C, human immunodeficiency virus infection and AIDS, etc. Dextran derivatives indeed change the pathology of infections dependent on DC-SIGN and mannose receptors. Complete knowledge of specific dextran–lectin interactions may also be important for development of future dextran applications in biological research and medicine.   This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.
url https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/22139
work_keys_str_mv AT sergeypustylnikov targetingthectypelectinsmediatedhostpathogeninteractionswithdextran
AT divyasagar targetingthectypelectinsmediatedhostpathogeninteractionswithdextran
AT poojajain targetingthectypelectinsmediatedhostpathogeninteractionswithdextran
AT zafarkkhan targetingthectypelectinsmediatedhostpathogeninteractionswithdextran
_version_ 1724530002379145216